Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions
04. Oktober 2023 16:05 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
29. September 2023 09:00 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium
14. September 2023 16:15 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
08. August 2023 16:05 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for...
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
25. Juli 2023 17:18 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for...
Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting
28. Juni 2023 16:05 ET
|
Zynerba Pharmaceuticals, Inc.
Annual Meeting Reconvened and Adjourned Without Conducting Business Meeting to Reconvene on July 27, 2023 at 9:00 am EDT DEVON, Pa., June 28, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc....
Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
20. Juni 2023 07:00 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., June 20, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting
13. Juni 2023 16:05 ET
|
Zynerba Pharmaceuticals, Inc.
Meeting adjourned with respect to Proposal 2, Reverse Stock Split; Company encourages additional stockholders of record to vote before reconvened meeting on June 28, 2023 All other proposals...
Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
23. Mai 2023 07:00 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., May 23, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights
15. Mai 2023 07:00 ET
|
Zynerba Pharmaceuticals, Inc.
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 $44.4 million in cash and cash...